Navigation Links
PDL BioPharma Announces December 15 Special Dividend Payment of $1.67 per Share
Date:12/2/2009

INCLINE VILLAGE, Nev., Dec. 2 /PRNewswire-FirstCall/ -- PDL BioPharma, Inc. (PDL) (Nasdaq: PDLI) today announced that it has established the per share amount of the previously announced $200 million special dividend as $1.67 per share. The dividend will be paid on December 15, 2009 to all holders of the Company's stock as of the December 1, 2009 record date. NASDAQ had previously estimated the approximate per share amount of the dividend at $1.67 per share of common stock for purposes of the ex-dividend date on November 27, 2009.

Conversion Rate Adjustments for Convertible Notes

In connection with this special dividend payment PDL has adjusted the conversion rates of its 2.00% Convertible Senior Notes Due February 15, 2012 (the 2012 Notes) and its 2.75% Convertible Subordinated Notes Due August 16, 2023 (the 2023 Notes), effective December 2, 2009.

The conversion rate for the 2012 Notes, as adjusted, is 119.294 shares of common stock per $1,000 principal amount or $8.38 per share. The conversion rate for the 2012 Notes was previously 94.447 shares of common stock per $1,000 principal amount of the 2012 Notes. In connection with a cash dividend, the conversion rate is increased by multiplying the previous conversion rate by a fraction, the numerator of which is the average closing price of PDL's common stock for the five consecutive trading days immediately preceding the ex-dividend date for the cash dividend, and the denominator of which is the difference of such average closing price less the dividend amount.

The conversion rate for the 2023 Notes, as adjusted, is 164.7254 shares of common stock per $1,000 principal amount or $6.07 per share. The conversion rate for the 2023 Notes was previously 131.0339 shares of common stock per $1,000 principal amount of the 2023 Notes. In connection with
'/>"/>

SOURCE PDL BioPharma, Inc.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related medicine technology :

1. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
2. Nabi Biopharmaceuticals Announces Second Quarter 2007 Financial Results
3. Nabi Biopharmaceuticals Announces Continued Positive NicVAX Phase 2b Data at Nine Months
4. Keryx Biopharmaceuticals to Present at William Blair & Company Small-Cap Growth Stock Conference
5. Morria Biopharmaceuticals Plc Initiates Phase I Clinical Study of MRX-4 in Allergic Rhinitis
6. Keryx Biopharmaceuticals, Inc. Announces Positive Preliminary Phase 2 Data on KRX-0401 in Patients with Chemo-Insensitive Rare Sarcoma
7. Nabi Biopharmaceuticals Announces Successful Completion of NicVAX(R) Phase 2b Trial; Drug Shows Statistically Significant Rates of Smoking Cessation and Continuous Long-Term Smoking Abstinence at 12 Months
8. Inspiration Biopharmaceuticals Announces Filing of IND for Novel Recombinant Factor IX Product, IB1001, for the Treatment of Hemophilia B
9. Immunosyn Announces Biozyme Labs Receipt of MHRA Manufacturing License Approval in Europe for the Biopharmaceutical SF-1019
10. Keryx Biopharmaceuticals, Inc. Announces Phase 1 and Phase 2 Data on KRX-0401 (Perifosine) in Patients with Relapsed/Refractory Multiple Myeloma at 49th Annual Meeting of American Society of Hematology
11. XTL Biopharmaceuticals Presents Data Regarding its Hepatitis C Virus Small Molecule Program at Hep Dart 2007 - an International Scientific Conference on Viral Hepatitis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/17/2013)... -- Fuse Science, Inc. (OTCQB: DROP), ( www.fusescience.com ) a ... patent-pending technologies poised to redefine how consumers receive energy, medicines, ... business update teleconference and webcast for shareholders and the investment ... PM ET. Fuse Science, Inc. CEO, ... will be joined by Rubin Hanan , ...
(Date:5/17/2013)... , May 17, 2013  Atossa Genetics, Inc. (NASDAQ: ... that Kyle Guse , Chief Financial Officer ... LLP MicroCap Conference on Thursday, May 30, 2013, in ... Hotel. The Company,s presentation is scheduled to ... a live webcast. To access the webcast, go to ...
(Date:5/17/2013)... BEIJING , May 17, 2013 Sinovac Biotech ... vaccines in China , today announced that ... quarter ended March 31, 2013, before market on Tuesday, May ... Tuesday, May 28, 2013, at 8:00 a.m. EDT (May 28, ... Company,s financial results and provide an update on recent corporate ...
Breaking Medicine Technology:Fuse Science, Inc. to Hold Business Update Webcast and Teleconference on May 22nd 2Atossa Genetics to Present at the Second Annual Marcum LLP MicroCap Conference 2Atossa Genetics to Present at the Second Annual Marcum LLP MicroCap Conference 3Sinovac to Host Conference Call to Report First Quarter 2013 Unaudited Financial Results 2Sinovac to Host Conference Call to Report First Quarter 2013 Unaudited Financial Results 3
... to be Dosed Shortly -, SAN DIEGO, March ... completion of the safety and,tolerability assessment of its third ... new HspE7 (HspE7 + Poly-ICLC) in patients with cervical,intraepithelial ... and met the limits prescribed in the trial protocol, ...
... will remain open until March 21, 2008, ... as,government agencies when implementing new policies, a national ... today,called for public comment on a series of ... trials., As part of the four year ...
Cached Medicine Technology:Nventa Evaluation Complete for First Three Cohorts in HspE7 Phase 1 Cervical Dysplasia Trial 2Nventa Evaluation Complete for First Three Cohorts in HspE7 Phase 1 Cervical Dysplasia Trial 3Nventa Evaluation Complete for First Three Cohorts in HspE7 Phase 1 Cervical Dysplasia Trial 4Nventa Evaluation Complete for First Three Cohorts in HspE7 Phase 1 Cervical Dysplasia Trial 5EDICT Opens Public Comment Period for Clinical Trials Policy Recommendations 2
(Date:5/18/2013)... Pomona, NY (PRWEB) May 18, 2013 Dr. ... sleep apnea dentistry, employs his knowledge of the ... in sleep apnea patients. With May being Better Sleep Month, ... have some sort of chronic sleep disorder, and sleep apnea ... With sleep apnea, a person will essentially stop breathing at ...
(Date:5/18/2013)... May 18, 2013 John Ravera, D.D.S., a ... addition of a new member to his dental team, Courtney ... in the field for over 10 years. She received her ... and was elected a member of Sigma Pi Alpha, a ... Marino enjoys working with patients of all ages, helping them ...
(Date:5/18/2013)... 2013 According to the the Stevens Johnson ... Epidermal Necrolysis, is a severe allergic reaction usually to medicine ... but it can quickly advance causing blistering and large areas ... death. SJS can develop at any time and seriously ... NBA player, Manute Bol, passed away after he received kidney ...
(Date:5/18/2013)... The product liability attorneys at Wright & Schulte have ... nationwide who have sustained serious tendon injuries allegedly caused by ... all part of MDL 2308 and were all filed on ... heard in the U.S. District Court of the Western District ... specializes in defending the rights of those who have suffered ...
(Date:5/17/2013)... (PRWEB) May 17, 2013 Daily Gossip announced ... with the creator of the Program Yourself Thin ... on their online website by the end of the month ... accomplish to successfully reeducate themselves and lead a healthy lifestyle, ... Program Yourself Thin package is available for only $97 ...
Breaking Medicine News(10 mins):Health News:Pomona, NY Dentist, Dr. Robert Tracey of General & Laser Assisted Dentistry (GLAD) Highlights Sleep Apnea Dentistry Services for Better Sleep Month 2Health News:Pomona, NY Dentist, Dr. Robert Tracey of General & Laser Assisted Dentistry (GLAD) Highlights Sleep Apnea Dentistry Services for Better Sleep Month 3Health News:Newport Beach Cosmetic Dentist John Ravera Adds New Member to Dental Team 2Health News:Injury Law Firm Announces New Informative Graphic on Common Medicines That Have Allegedly Been Linked to Stevens Johnson Syndrome 2Health News:Ten Skechers Lawsuits Filed by Wright & Schulte on Behalf of Consumers Who Sustained Severe Tendon Damage Allegedly Due to Wearing Skechers Shape-Ups 2Health News:Ten Skechers Lawsuits Filed by Wright & Schulte on Behalf of Consumers Who Sustained Severe Tendon Damage Allegedly Due to Wearing Skechers Shape-Ups 3Health News:Ten Skechers Lawsuits Filed by Wright & Schulte on Behalf of Consumers Who Sustained Severe Tendon Damage Allegedly Due to Wearing Skechers Shape-Ups 4Health News:Program Yourself Thin Review and Secrets Revealed By Daily Gossip Magazine 2
... its key inflammatory mediators (IL-12 and IL-23) is highly ... researchers. ,Current treatments for psoriasis include ... symptoms of the disease. Many of these treatments are ... very effective, according to Gerald Krueger, M.D., principal investigator ...
... extreme losses -- in two cases, greater than $100,000 -- ... been linked to a class of drugs commonly used to ... Mayo Clinic study is the first to describe this compulsive ... that stimulate dopamine receptors in the brain. ,The ...
... A botched up family planning operation would have claimed one ... of Indian origin// wasn't there to perform a lifesaving surgery. ... 300 km from here, was a boon for Vijayanti Devi, ... was cut out by mistake during a routine family planning ...
... set to start its manufacturing facility in the ... drug market. ,Ind-Swift Laboratories has completed ... its Clarithromycin active pharmaceutical ingredient (API) manufacturing unit, ... ,Clarithromycin is a macrolide antibiotic molecule ...
... diagnosis laboratories and counselling centres in various hospitals as HIV ... ,The decision was announced at the second meeting of the ... UNB reported. ,The meeting, chaired by health advisor ... policy, said a press release. ,The meeting decided ...
... of diseases or disorders of the valves in the heart ... caused by diseases such as rheumatic fever, or degenerative// conditions ... for valvular heart disease (VHD) highlight the need for improvement ... chair of the European Society of Cardiology (ESC) task force ...
Cached Medicine News:Health News:New Treatment For Psoriasis Is Highly Effective 2Health News:Medications for Restless Legs Syndrome may Trigger Compulsive Gambling 2Health News:Medications for Restless Legs Syndrome may Trigger Compulsive Gambling 3Health News:New Guidelines for VHD 2Health News:New Guidelines for VHD 3Health News:New Guidelines for VHD 4
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
Medicine Products: